NovImmune: Novimmune's lead drug on the way to the market

Novimmune, a Swiss biotech company focused on the discovery and development of antibody-based drugs, has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) seeking marketing approval for its lead compound, emapalumab, for the treatment of patients with primary Hemophagocytic Lymphohistiocytosis (HLH).